Literature DB >> 19189853

PKR protein kinase is activated by hepatitis C virus and inhibits viral replication through translational control.

Ju-Il Kang1, Shi-Nae Kwon, Se-Hoon Park, Yun Ki Kim, Sang-Yun Choi, Jungsuh P Kim, Byung-Yoon Ahn.   

Abstract

Hepatitis C virus (HCV) infection is currently treated with IFNalpha-based therapy but little is known how IFNalpha inhibits HCV replication. We show here that HCV JFH1 infection of human hepatoma Huh-7 cells leads to the activation of IFN-inducible protein kinase PKR and phosphorylation of the translation initiation factor eIF2alpha. Compared to a control cell HCV replication was significantly elevated in a PKR-knockdown cell, giving rise to a 10-fold higher viral titer, and was less sensitive to IFNalpha treatment. Conversely, transient expression of PKR inhibited HCV replication in a kinase-dependent manner with concomitant increase of eIF2alpha phosphorylation. Further, expression of a phospho-mimetic eIF2alpha mutant moderately inhibited HCV replication. Together, these results demonstrate that PKR is activated by HCV infection and plays a critical antiviral role through inhibition of viral protein translation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19189853     DOI: 10.1016/j.virusres.2009.01.007

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  20 in total

Review 1.  Tinkering with translation: protein synthesis in virus-infected cells.

Authors:  Derek Walsh; Michael B Mathews; Ian Mohr
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-01-01       Impact factor: 10.005

2.  Hepatitis C virus infection impairs IRF-7 translocation and Alpha interferon synthesis in immortalized human hepatocytes.

Authors:  Amit Raychoudhuri; Shubham Shrivastava; Robert Steele; Srikanta Dash; Tatsuo Kanda; Ranjit Ray; Ratna B Ray
Journal:  J Virol       Date:  2010-09-01       Impact factor: 5.103

3.  PKR-dependent mechanisms of interferon-α for inhibiting hepatitis B virus replication.

Authors:  Il-Hyun Park; Kyung-Won Baek; Eun-Young Cho; Byung-Yoon Ahn
Journal:  Mol Cells       Date:  2011-06-23       Impact factor: 5.034

4.  eIF2A mediates translation of hepatitis C viral mRNA under stress conditions.

Authors:  Joon Hyun Kim; Sung Mi Park; Ji Hoon Park; Sun Ju Keum; Sung Key Jang
Journal:  EMBO J       Date:  2011-05-10       Impact factor: 11.598

5.  Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation.

Authors:  Urtzi Garaigorta; Francis V Chisari
Journal:  Cell Host Microbe       Date:  2009-12-17       Impact factor: 21.023

6.  Hepatitis C virus controls interferon production through PKR activation.

Authors:  Noëlla Arnaud; Stéphanie Dabo; Patrick Maillard; Agata Budkowska; Katerina I Kalliampakou; Penelope Mavromara; Dominique Garcin; Jacques Hugon; Anne Gatignol; Daisuke Akazawa; Takaji Wakita; Eliane F Meurs
Journal:  PLoS One       Date:  2010-05-11       Impact factor: 3.240

7.  Ultra-structural localisation of hepatocellular PKR protein using immuno-gold labelling in chronic hepatitis C virus disease.

Authors:  Gerry C MacQuillan; Paul Caterina; Bastiaan de Boer; Jane E Allan; Michael A Platten; William D Reed; Gary P Jeffrey
Journal:  J Mol Histol       Date:  2009-07-30       Impact factor: 2.611

8.  Suppression of Host Innate Immune Response by Hepatitis C Virus via Induction of Autophagic Degradation of TRAF6.

Authors:  Stephanie T Chan; Jiyoung Lee; Mansi Narula; J-H James Ou
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

Review 9.  Innate immune responses in hepatitis C virus infection.

Authors:  Kui Li; Stanley M Lemon
Journal:  Semin Immunopathol       Date:  2012-08-07       Impact factor: 9.623

10.  Hepatitis C virus (HCV) induces formation of stress granules whose proteins regulate HCV RNA replication and virus assembly and egress.

Authors:  Urtzi Garaigorta; Markus H Heim; Bryan Boyd; Stefan Wieland; Francis V Chisari
Journal:  J Virol       Date:  2012-08-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.